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Abstract
Intradetrusor injection of onabotulinum A toxin (BTX-A) is an 
effective regimen for the highly prevalent condition in wom-
en of overactive bladder. The optimal dose of BTX-A has not 
been definitively established. Women (n = 13) with overac-
tive bladder including urge incontinence refractory to at least 
two different oral/transdermal anticholinergic regimens and 
who had idiopathic detrusor overactivity were randomized to 
100-unit and 200-unit doses utilizing a double-blinded cross-
over design. One woman (100-unit dose) experienced pro-
longed urinary retention. For the remaining patients, quality 
of life parameters estimated using the overactive bladder 
questionnaire baseline showed no significant difference be-
tween either dose regimen at 3, 6, 9 and 12 months follow 
up. Urodynamic data were recorded at (pre-treatment) and 
at 3 months after each treatment. Mean (SD) volume at first 
leakage was 178 (82) ml and 327 (115) ml for 200 units and 
226 (131) ml and 215 (139) ml for 100 units (p < 0.001). 
Significant differences (p < 0.05) between baseline and 3 
months in favour of the 200-unit dose were also observed 
in bladder capacity; volume at first urgency sensation; vol-
ume at first detrusor contraction. Changes in voiding param-
eters between baseline and 3 months for maximal flow rate, 
maximal detrusor pressure, and post-void residual volume 
were not significantly different for the two doses. Mean (SD) 
maximal voided volumes recorded on the patients’ bladder 
diaries were 178 (82) ml and 327 (115) ml for 200 units and 
226 (131) ml and 215 (139) ml for 100 units (p < 0.001). The 
following bladder diary parameters were not significantly dif-
ferent: daytime frequency; nocturia; incontinence episodes. 
Thus, for the subset of women with idiopathic detrusor over-
activity, although urodynamic parameters suggest 200 units 
to be superior, this did not translate to any clinically mean-
ingful improvement over 100 units.
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Introduction
Overactive Bladder (OAB) defined jointly by the International 
Continence Society and International Urogynaecological 
Association (ICS/IUGA) is the unexplained clinical syndrome 
encompassing the symptoms of urinary urgency, frequency 
and nocturia, with or without urge urinary incontinence 
[1]. OAB has an estimated prevalence of 12.8% - 43.1% 
in adult women and 10.8% - 27.2% in adult men [2]. The 
overrepresentation of women is presumably related to 
factors such as anatomical differences (e.g. short female 
urethra), childbirth-related injury, hormonal effects, and 
psychological effects in some women, e.g. those who have 
experienced or continue to experience violence and sexual 
abuse. The broad range of treatment options for OAB attest 
to the difficulty in managing this condition. Non-invasive 
treatments for OAB include behavioural modification, 
e.g. attention to fluid intake, timed voiding, and weight 
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unit in Adelaide, Australia. These women had initially 
presented elsewhere for management of OAB and 
were later referred to our unit following failure of first 
line regimens. BTX-A was not at the commencement 
of this trial approved in Australia for the intended use, 
hence, approval for “off label” use was obtained from 
the Australian Therapeutic Goods Administration (TGA). 
At our institution, the use of “off label” regimens also 
required ethics approval and formal evaluation for hospital 
funding of the regimen. TGA approval was obtained in 
2007. Originally, we planned a simple, randomised, cross-
sectional design - i.e., one dose, either 100 U or 200 U for 
each recruited patient. At that time, there were no data 
available to make power calculations. Based on our clinical 
load and an estimated 50% recruitment of patients with 
IDO, we expected we would in 2 years have completed 
40 observations. That would have allowed a preliminary 
analysis of sufficient sample size from which to estimate 
the treatment effect and determine if the study was 
completed, viable but to continue, or non-viable and to 
cease. Recruitment of women to the trial proved difficult, 
primarily as most were not willing to accept the risk of 
prolonged urinary retention requiring clean intermittent 
self-catheterisation. We obtained expert statistical opinion, 
which was that switching to the crossover design described 
below would allow a greater probability of reaching a 
satisfactory conclusion with a smaller number of patients. 
We planned to undertake preliminary analysis after 20 
patients had completed the crossover protocol. This 
required new ethics approval and the earlier cross-sectional 
data we had were unable to be used. Recruitment to the 
crossover trial also was slow and the study eventually was 
abandoned with our data reported here.
Methodology
Women with OAB who had confirmed, Idiopathic 
Detrusor Overactivity (IDO), normal voiding, and who had 
previously not responded to at least two anticholinergic 
regimens, and who did not have urodynamic stress 
incontinence were eligible for entry to the trial.
Full exclusion criteria are shown in Table 1. Although 
the patients were to be selected only if they had IDO, we 
treat symptoms, so the primary endpoint was quality 
of life (QoL). QoL was measured using the validated 
overactive bladder Quality of Life questionnaire (OABq) 
[23]. The OABq has two components - the Quality of Life 
Index (Range 0 - 100, higher numbers indicating better 
quality of life) and the Symptom Severity Index (range 
0 - 100, higher numbers indicating greater severity of 
symptoms). Patients completed the OABq at baseline, 
6 weeks, 3 months and thereafter 3-monthly up until 
12 months or until “treatment failure”. BTX-A loses 
its effect at variable intervals. Such loss of effect was 
defined as “treatment failure” - a subjective secondary 
endpoint. Other secondary endpoints were changes in 
bladder diary data and urodynamic data between pre-
test baseline and repeated measures after treatment. 
pharmacological regimens such as anticholinergics, alpha 
adrenergic agonists, and intravaginal oestrogen. Treatments 
to improve mobility and availability and mapping of utilities 
such as public toilets might help to prevent “accidents” due to 
urge incontinence. People of both genders who can’t control 
urge incontinence will resort to incontinence aids such as 
pads, which are expensive and often uncomfortable. The 
condition often affects normal daily activities and sleeps and 
is a source of shame, embarrassment and social withdrawal. 
Quality of Life (QoL) is adversely affected and the prevalence 
of concomitant depression is increased [3]. Unfortunately, 
the non-invasive treatments described are often ineffective 
or the response to treatment suboptimal. This has driven 
the development of invasive treatments including sacral 
neuromodulation and the intradetrusor injection of 
botulinum A toxin.
There have been several reports published since 
2005 on the use of Onabotulinum A Toxin (BTX-A) by 
intradetrusor injection for patients with neurogenic 
or idiopathic detrusor overactivity [4-10]. These data 
confirm superiority of BTX-A over placebo but were 
not definitive regarding the optimal dose, which were 
typically in the range of 50 - 200 units for IDO and 200 - 
300 units for NDO.
Dose-ranging studies for BTX-A in management of 
OAB and with 8 or more episodes of urge incontinence 
a week concluded that a dose of 100 units optimally 
balances efficacy and risk of retention defined by arbi-
trary post void residual volumes [11,12]. The duration 
of benefit is variable, though efficacy is maintained with 
repeat treatments [13-19].
BTX-A by intradetrusor injection is now an established 
regimen for the treatment of OAB, and was approved in 
the United States by the FDA in 2014 for this purpose. 
In the USA, national guidelines are to use a dose of 100 
units for OAB [19]. This contrasts with the National 
Institute of Clinical Excellence (UK) guidelines, which 
recommend 200 units [20]. Internationally, for OAB the 
optimal dose of BTX-A is not yet established [21].
In this trial, it was sought to establish which of two 
doses of BTX-A was the preferred option in manage-
ment of women with OAB with concomitant urge incon-
tinence and who had IDO (as defined by ICS/IUGA) con-
firmed by urodynamic testing. The appropriateness of a 
policy of advising clean intermittent self-catheterisation 
determined by arbitrary post-void residual volumes has 
recently been challenged [22]. We did not set an arbi-
trary limit to post-void residual volumes and treated on 
symptoms alone. Thus, we hypothesised that the 200-
unit dose might prove superior with extended efficacy 
as determined by the patients’ QoL.
Methods and Materials
Context
This trial was undertaken in the Royal Adelaide Hospital 
(RAH) - a publically-funded tertiary referral adult gynaecology 
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and has achieved good compliance compared with longer 
intervals.
In this double-blind, randomized crossover trial 
(Figure 1), patients were centrally randomized in the 
hospital pharmacy to receive either 100- or 200-units 
at the first round of treatment and the opposite dose 
Patients were asked to record in their bladder diaries the 
times and amounts of fluid drunk and urine voided, and 
the time and nature of any abnormal urinary symptoms 
for 48 consecutive hours at the same time as recording 
OABq data. The 48-hour period of observation has in our 
experience been the most patient-friendly compromise 
Table 1: Exclusion criteria for eligibility to enroll in the trial.
Coexisting, untreated urinary stress incontinence
Concomitant use of:
•	 Anticholinergic regimens (to cease two weeks prior to treatment and remain off for 6 weeks post treatment)
•	 Anticoagulant or antiplatelet regimens (to cease pre-treatment and resume day 1 post treatment)
•	 Diuretics
Dementia
Hydronephrosis, post-void residual volume > 100 ml, or another urinary tract anomaly 
Neurogenic detrusor overactivity
Pre-existing voiding abnormalities defined in the urodynamic clinic as either of: 
•	 Uroflowmetry parameters (mean and maximal flow rates) < 10 centile for age and gender (Liverpool nomogram)
•	 Post-void residual volumes > 100 ml
Pregnancy
Surgery for incontinence, vaginal prolapse or hysterectomy within 6 months of recruitment
Stroke or other cerebrovascular accident 
Urinary tract infection
Unstable Diabetes 














Figure 1: Flow diagram of the crossover design.
OAB: Overactive Bladder; AC: Anticholinergic; IDO: Idiopathic Detrusor Overactivity; UDS: Urodynamic Studies; Rx: Treatment; 
Btx: Onabotulinum A Toxin.
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undertaken using the paired t-test and for other data 
by multivariate ANOVA. The duration of effect was es-
timated by computing the time taken following treat-
ment for decay in the OABq Quality of Life Index to 20% 
above the baseline, or sooner if the patient requested 
to have the second treatment. These data were plotted 
using cumulative survival (Kaplan-Meier) analysis.
Results
Mean (SD) age at entry was 58 (13) years. One 
patient was indigenous Australian and the remainder 
white Caucasian. 12 of 13 women enrolled had both 
doses of BTX-A administered. One woman who received 
100 units for the first treatment went in to prolonged 
urinary retention requiring catheterisation for 8 months 
and did not continue in the trial. Data were obtained 
from all remaining participants at baseline and 
3-months post treatment. OABq data were available 
for 8 of the 12 patients at 9 months post-treatment, 
with the remainder having reported “treatment failure” 
before then. The full summary data for the Quality 
of Life and Severity Indices are shown in Table 2 and 
Table 3. For the Quality of Life Index, at 3 months post 
treatment, the mean (SD) difference was 1 (36) unit in 
favour of the 200-unit dose (this negligible difference 
was not statistically significant, p = 0.89). At 9 months 
at the second (final) round of treatment. The timing of 
the second treatment was determined once the patient 
reported return of symptoms and was requesting re-
treatment. A repeat baseline evaluation including 
repeat urodynamic testing was arranged prior to the 
second intradetrusor injection of BTX-A. Women for 
whom treatment was successful have continued to 
receive treatment since the completion of the trial.
The BTX-A was diluted in 20 ml normal saline 
by pharmacy staff not otherwise involved in the 
trial and presented in a pre-filled 20 ml syringe in 
operating theatre labelled as BTX-A and with the 
patient’s identifying information. The dilute BTX-A 
was administered by intradetrusor injection in 20 1ml 
aliquots in a 5 × 4 grid pattern with approximately equal 
spacing (avoiding visible subendothelial blood vessels) 
via a Williams 23 g cystoscopy needle and 30-degree, 
rigid cystoscope using a trigone sparing technique. 
Neither the patient, operating theatre staff, nor the 
researcher, had knowledge of the dose administered. 
The code held by pharmacy was only made available 
to the researcher once all follow up data had been 
collected.
Statistical analysis was undertaken using IBM® SPSS® 
for Mac version 24. Analysis for paired OABq data was 
Table 3: Baseline and post treatment Severity Index (Overactive Bladder Questionnaire) for 100- and 200-unit doses of botulinum 
A toxin by intradetrusor injection for women with idiopathic detrusor overactivity. 
Severity Index Dose Mean Std. Error 95% Confidence Interval
Lower Bound Upper Bound
Baseline 100 62.3 9.7 35.4 89.2
200 64.7 9.7 37.8 91.5
Six Weeks 100 2.3 2.2 -3.7 8.4
200 3.3 2.2 -2.7 9.4
Three Months 100 4.3 3.4 -5.1 13.7
200 3.3 3.4 -6.1 12.7
Six Months 100 4.3 4.6 -8.6 17.2
200 8.0 4.6 -4.9 20.9
Nine Months 100 6.7 6.0 -10.0 23.3
200 12.0 6.0 -4.6 28.6
Twelve Months 100 10.0 11.2 -21.1 41.1
200 16.7 11.2 -14.4 47.7
Table 2: Baseline and post treatment Quality of Life Index (Overactive Bladder Questionnaire) for 100- and 200-unit doses of 
botulinum A toxin by intradetrusor injection for women with idiopathic detrusor overactivity.
Quality of Life Index Dose Mean Std. Error 95% Confidence Interval
Lower Bound Upper Bound
Baseline 100 48.6 13.3 11.8 85.5
200 38.0 13.3 1.1 74.9
Six Weeks 100 98.0 2.2 92.0 104.0
200 96.3 2.2 90.3 102.4
Three Months 100 97.0 2.7 89.4 104.5
200 96.7 2.7 89.1 104.2
Six Months 100 99.7 2.7 92.3 107.1
200 94.3 2.7 86.9 101.7
Nine Months 100 97.3 4.2 85.7 109.0
200 90.0 4.2 78.4 101.6
Twelve Months 100 96.0 6.5 77.8 114.1
200 90.7 6.5 72.5 108.9
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and 3 months were not significantly different for the 
two doses.
Bladder diary parameters at baseline and at 3 
months are shown in Table 5. The maximal voided volume 
increased to a significantly greater extent with the 200-
unit regimen (p = 0.04) but there was no difference in 
daytime frequency, nocturia or episodes of incontinence 
between dose regimens.
Discussion
This trial was established to determine the optimal 
dose of BTX-A given by intradetrusor injection in the 
subset of women presenting with refractory overactive 
bladder and who had an urodynamic diagnosis of 
idiopathic detrusor overactivity. It was assumed that 
either regimen would prove effective, or that BTX-A 
would in time be introduced as a standard option in 
clinical practice in our unit. As we would not have the 
funds or other capacity to offer a BTX-A regimen to 
every patient with OAB, we restricted eligibility to 
women with OAB with urge incontinence refractory to 
two or more oral/transdermal anticholinergic regimens 
and who had IDO and in the absence of stress urinary 
incontinence, which is a confounder. We did not set an 
arbitrary limit to post-void residual volumes and treated 
on symptoms alone. We hypothesised that the 200-
unit dose might have superior efficacy as determined 
by the patients’ QoL (the primary endpoint) given we 
were not arbitrarily recommending intermittent self-
post treatment, there was no difference in quality of life 
with either dose. For the Severity Index, at 3 months 
post treatment, the mean (SD) difference was 10 (37) 
favouring the 100-unit dose (difference not significant, 
p = 0.63). At 9 months post treatment, this difference 
was 7 (33), also favouring the 100-unit dose (difference 
not significant, p = 0.56). Thus, for the primary endpoint 
100-units was equally effective as 200 units.
Survival analysis (Figure 2) calculated from the quality 
of life data shows a progressive decline in therapeutic 
effect over the 12 months of formal observation after 
each treatment. There was no difference in the rate of 
decline in effect between the two doses. 5 patients in 
both treatment groups reported persisting improvement 
at 12 months and did not require retreatment by the 
conclusion of this formal period of observation. 2 
patients experienced this prolonged response with both 
doses.
Analysis based on the effect of the sequence of 
treatment (i.e. 100 units first or 200 units first) was 
undertaken and showed no effect, but the power of this 
observation was low.
Urodynamic data at baseline and 3 months post 
treatment are shown in Table 4. Volume at first leakage, 
cystometric bladder capacity, volume at first urgency 
sensation and volume at first detrusor contraction were 
all more favourable with the 200-unit dose regimen (p < 
0.05). Changes in voiding parameters between baseline 
         





















Figure 2: Duration of response to treatment (Cum Survival) determined by 20% or greater improvement over baseline of the Quality 
of Life index (Overactive Bladder Questionnaire) for 100- and 200-unit doses of botulinum a toxin by intradetrusor injection for 
women with idiopathic detrusor overactivity.
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Table 4: Cystometry, uroflowmetry and pressure-flow study parameters at baseline and 3 months following treatment.
Urodynamics Parameters - Cystometry Baseline Three Months p value
Volume Fill 
- 100 units 285 (126) 333 (162)
- 200 units 203 (98) 416 (120) 0.001
Volume First Sensation
- 100 units 117 (68) 170 (110)
- 200 units 108 (53) 238 (116) 0.06
Volume First Urgency Sensation
- 100 units 167 (105) 220 (125)
- 200 units 151 (95) 287 (113) 0.04
Volume First Detrusor Contraction
- 100 units 207 (110) 261 (156)
- 200 units 150 (91) 287 (115) < 0.05
Volume First Leakage
- 100 units 226 (131) 215 (139)
- 200 units 178 (82) 327 (115) < 0.001
Urodynamics Parameters -Uroflowmetry/Pressure Flow Studies
Volume Post Void Residual (averaged over two measures)
- 100 units 36 (70) 72 (98)
- 200 units 24 (39) 75 (97) 0.66
Maximal Flow Percentile
- 100 units 43 (24) 43 (36)
- 200 units 55 (29) 58 (31) 0.62
Maximal Detrusor Pressure
- 100 units 72 (82) 42 (27)
- 200 units 36 (21) 37 (27) 0.30
Table 5: 48-hour bladder diary parameters at baseline and 3 months post treatment.
Frequency Volume Chart Parameters Baseline Three Months p value
Frequency (awake)
- 100 units 11.0 (4.3) 8.7 (2.9)
- 200 units 9.9 (3.8) 7.2 (2.8) 0.84
Nocturia
- 100 units 2.5 (2.1) 1.6 (1.6)
- 200 units 2.7 (1.4) 1.4 (1.4) 0.23
Number of Times Incontinent
- 100 units 6.2 (5.3) 1.4 (2.7)
- 200 units 7.9 (4.8) 1.3 (3.6) 0.41
Maximal Voided Volume
- 100 units 331 (112) 340 (147)
- 200 units 328 (71) 464 (162) 0.04
life index was miniscule or absent (between 0 to 1 unit 
mean difference in a 100-unit range), it is very unlikely 
if larger numbers of patients had been studied that the 
conclusions would change. This can be corroborated by 
inspection of the survival analysis plot. By 12 months 
38% of patients in either dose regimen was still happy 
with their bladder control - indicating natural self-
selection for a favourable response in that subgroup, 
for reasons unexplained. This finding is consistent with 
observations by others [24].
A risk of intradetrusor BTX-A is prolonged post-
catheterisation in asymptomatic women.
The primary endpoint QoL was chosen because that 
is what patients hope to improve in undergoing such 
therapies and the OABq instrument chosen as it has 
been previously validated in the group of interest. The 
principal finding was that there was no difference in 
the primary endpoint whether a 100- or 200-unit dose 
was employed. This is counterintuitive, and the data 
bear examination to consider whether small numbers 
are responsible for this conclusion. i.e. a type I error. 
As the magnitude of the difference in the quality of 
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This study was approved by the Ethics Committee of 
the Royal Adelaide Hospital and the Ethics of Human Re-
search Committee of the University of Adelaide.
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